• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Ragard John Phillip converted options into 4,843 shares, increasing direct ownership by 4% to 129,890 units (SEC Form 4)

    4/1/25 6:42:33 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AWH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ragard John Phillip

    (Last) (First) (Middle)
    C/O ASPIRA WOMEN'S HEALTH INC
    12117 BEE CAVES RD, BLDG 3-100

    (Street)
    AUSTIN, TX 78738

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aspira Women's Health Inc. [ AWH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/31/2025 M(1) 4,843 A $0 129,890 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 03/31/2025 M 4,843 (3) (3) Common Stock 4,843 $0 4,844 D
    Explanation of Responses:
    1. Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,843 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.
    2. Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.
    3. On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,843 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.
    /s/ John Phillip Ragard 04/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AWH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AWH

    DatePrice TargetRatingAnalyst
    1/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      7/11/24 5:15:45 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/18/24 4:12:21 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/3/24 5:30:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Aspira Women's Health Inc.

      S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/30/25 8:10:19 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFR14A filed by Aspira Women's Health Inc.

      DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/22/25 4:05:41 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Aspira Women's Health Inc. (0000926617) (Filer)

      4/16/25 5:07:30 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

      Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00

      1/12/22 7:53:25 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Truist Securities initiated coverage on Aspira Womens Health with a new price target

      Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00

      3/29/21 7:32:28 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

      Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00

      1/29/21 6:12:39 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/28/25 7:19:40 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Hundorfean Cynthia D

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/24/25 9:41:23 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/2/25 8:23:47 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aspira Women's Health Inc.

      SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)

      11/14/24 3:23:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      7/11/24 5:14:26 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      6/18/24 4:13:01 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Leadership Updates

    Live Leadership Updates

    See more
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

      AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

      9/5/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

      AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

      7/29/24 9:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Financials

    Live finance-specific insights

    See more
    • Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

      Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

      11/14/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

      AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

      11/4/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

      AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

      7/31/24 4:05:00 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

      Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

      1/10/25 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

      AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

      12/3/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care